Davis Polk & Wardwell LLP is advising Citigroup Global Markets, Inc. as lead arranger of a $925 million unsecured, investment-grade bridge facility to Laboratory Corporation of America Holdings in connection with its $925 million acquisition of Genzyme Genetics, a business unit of Genzyme Corp. Genzyme Genetics is a leading provider of complex reproductive and oncology testing services. The business performs more than 1.5 million high-quality, high-clinical value tests annually with reported revenue in 2009 of approximately $371 million.

Laboratory Corporation of America Holdings, an S&P 500 company that has over 28,000 employees worldwide, performs a range of clinical tests from routine blood analyses to HIV and genomic testing and specializes in developing diagnostic technologies. The company had an annual revenue of $4.7 billion in 2009.

The Davis Polk financing team includes partner Jason Kyrwood and associates Louise C. Bennetts, Darren Mahone and Stevan R.B. Nicholas. The Davis Polk capital markets team includes partner John G. Crowley and associates Sarah Ashfaq and Scott Lunin. All members of the Davis Polk team are based in the New York office.

Hogan Lovells US LLP acted as counsel to Laboratory Corporation of America Holdings and Ropes & Gray LLP is acting as counsel to the seller.